MedPath

Kures, Inc.

Kures, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
2017-01-01
Employees
1
Market Cap
-
Website
http://www.kuresinc.com

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of KUR-101 in Healthy Adults

Phase 1
Completed
Conditions
Acute Pain
Interventions
Drug: OxyNorm
Drug: Placebo
First Posted Date
2021-11-09
Last Posted Date
2022-12-14
Lead Sponsor
Kures, Inc.
Target Recruit Count
60
Registration Number
NCT05114265
Locations
🇳🇿

KUR-101-101 Clinical Research Site, Christchurch, New Zealand

© Copyright 2025. All Rights Reserved by MedPath